Abstract
Fungal infections represent a major global threat, yet to date there are no vaccines to any pathogenic fungi. The commensal pathobiont Candida albicans was designated a WHO priority pathogen due to its capacity to cause severe morbidity and mortality. In immunocompromised individuals, C. albicans can also cause severe oropharyngeal and mucocutaneous candidiasis. In oropharyngeal candidiasis (OPC), oral epithelial cells (OECs) are the first point of interaction with fungus. Upon encounter with C. albicans , OECs upregulate a large array of anti-fungal defense genes. There are extensive studies characterizing transcriptional mechanisms that lead to expression of cytokines, chemokines, antimicrobial peptides, etc. within OECs. Inflammatory transcripts are subject to extensive regulation at the mRNA level, yet surprisingly little is known about mechanisms that control C. albicans -induced genes posttranscriptionally. Recently, the importance of mRNA modifications (the "epitranscriptome") in immunity has become appreciated, but almost nothing is known about this in the setting of fungal infection. Here, we demonstrate a role for N6-methyladenosine (m (6) A) RNA modification in oral epithelial defense responses to C. albicans . Blockade of core m (6) A machinery including methylases ('writers') and m (6) A binding proteins ('readers') results in reprogramming of essential C. albicans host defense transcripts. In particular, the YTHDF family of m (6) A readers represses a subset of OEC immune genes but upregulates others. Pharmacological inhibition of METTL3, a core m (6) A writer, murine OPC leads to increased cytokine gene expression, resulting in reduced fungal burden and alleviating disease. These studies provide insights into mechanisms through which m (6) A modifications contribute to host epithelial responses to C. albicans , establishing a role for the m (6) A pathway as a bidirectional modulator of immunity to mucosal candidiasis.